



LEI: 549300Q7EXQQH6KF7Z84

2 January 2026

**RTW Biotech Opportunities Ltd**  
(the "Company")

### **Total Voting Rights**

In accordance with DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the Company notifies the following:

As at the close of business on 31 December 2025, the Company had 345,967,440 Ordinary Shares in issue, of which 19,593,791 were held in treasury. Therefore, the total number of voting rights in the Company at that date was 326,373,649.

The above figure of 326,373,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

#### **Enquiries:**

<b>RTW Investments, LP - Investment Manager</b>	+44 (0)20 7959 6361
Oliver Kenyon (Business & Corporate Development)	biotechopportunities@rtwfunds.com
Woody Stileman (Business Development)	
Krishna McCune (Investor Relations)	
<b>Altum (Guernsey) Limited</b>	+44 (0)1481 703 100
Joanna Duquemin Nicolle	
Sadie Morrison	

#### **About RTW Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRLFLFXELLFFBV